Report #2883086

Received Jan 24, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Not recovered
Vaccinated: Jan 20, 2026
Onset: Jan 20, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	4AB32	—

Symptoms (6)

ErythemaFatigueHeadacheNauseaPainSwelling

Symptom narrative

pain; swelling; redness; headache; nausea; fatigue; This non-serious case was reported by a consumer and described the occurrence of pain in a 50-year-old female patient who received Herpes zoster (Shingrix) (batch number 4AB32) for prophylaxis. Concomitant products included bupropion hydrochloride (Bupropion). On 20-JAN-2026, the patient received Shingrix .5 ml. On 20-JAN-2026, less than a day after receiving Shingrix, the patient experienced pain (Verbatim: pain), swelling (Verbatim: swelling), erythema (Verbatim: redness), headache (Verbatim: headache), nausea (Verbatim: nausea) and fatigue (Verbatim: fatigue). The outcome of the pain was unknown and the outcome of the swelling, erythema, headache, nausea and fatigue were not resolved. It was unknown if the reporter considered the pain, swelling, erythema, headache, nausea and fatigue to be related to Shingrix. It was unknown if the company considered the pain, swelling, erythema, headache, nausea and fatigue to be related to Shingrix. Additional Information: GSK Receipt Date: 21-JAN-2026 The patient had pain, swelling, redness, headache, nausea and fatigue and the symptoms were not treated.

Other medications

BUPROPION